Copyright
©2013 Baishideng Publishing Group Co.
World J Gastrointest Pharmacol Ther. Aug 6, 2013; 4(3): 54-60
Published online Aug 6, 2013. doi: 10.4292/wjgpt.v4.i3.54
Published online Aug 6, 2013. doi: 10.4292/wjgpt.v4.i3.54
Table 2 Sustained virological response rates according to total ribavirin dose in each inosine triphosphatase genotype
| ITPA genotype (rs1127354) | Patients with > 60% total RBV dose | Patients with < 60% total RBV dose | Total |
| CA + AA | 48.3% (14/29) | 12.5% (1/8) | 40.5% (15/37) |
| CC | 58.5% (31/53) | 20.0% (6/30) | 44.6% (37/83) |
-
Citation: Fujino T, Aoyagi Y, Takahashi M, Yada R, Yamamoto N, Ohishi Y, Nishiura A, Kohjima M, Yoshimoto T, Fukuizumi K, Nakashima M, Kato M, Kotoh K, Nakamuta M, Enjoji M. Association of
ITPA polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy. World J Gastrointest Pharmacol Ther 2013; 4(3): 54-60 - URL: https://www.wjgnet.com/2150-5349/full/v4/i3/54.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v4.i3.54